Skip to main content
HIKMA Pharmaceuticals PLC logo

HIKMA Pharmaceuticals PLC — Investor Relations & Filings

Ticker · HIK ISIN · GB00B0LCW083 LEI · 549300BNS685UXH4JI75 IL Manufacturing
Open in API
Filings indexed 827 across all filing types
Latest filing 2025-03-19 Annual Report
Country GB United Kingdom
Listing IL HIK

About HIKMA Pharmaceuticals PLC

https://www.hikma.com/home/

Hikma Pharmaceuticals is a global pharmaceutical company that develops, manufactures, and markets a broad portfolio of pharmaceutical products. The company's offerings include a wide range of generic, branded, specialty, and in-licensed medicines. It is a significant supplier of generic injectable products to hospitals and also provides oral generics and other specialty medications. With a focus on producing high-quality medicines, Hikma aims to make its products accessible to patients and healthcare providers across its key markets in North America, Europe, and the Middle East & North Africa (MENA) region.

Recent filings

Filing Released Lang Actions
2024 Annual Report and Accounts
Annual Report Classification · 100% confidence The document is explicitly titled 'Hikma Pharmaceuticals PLC Annual Report 2024'. It contains comprehensive sections including a strategic report, business and financial review, corporate governance report, and audited financial statements. It provides detailed financial highlights, segmental performance, and management commentary for the full fiscal year 2024. It meets all criteria for an Annual Report (10-K equivalent). FY 2024
2025-03-19 English
Director/PDMR Shareholding
Remuneration Information Classification · 99% confidence The document is a regulatory filing disseminated via RNS (RNS Number : 3056Z) dated March 4, 2025. The content explicitly details 'Notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMRs) regarding the vesting and exercise of conditional share awards under the Executive Incentive Plan (EIP). This type of filing, which reports personal share transactions by directors and executives, directly corresponds to the definition of Director's Dealing.
2025-03-04 English
Final Results
Earnings Release Classification · 100% confidence The document is an 'Earnings Release' (ER) from Hikma Pharmaceuticals PLC. It contains the initial announcement of financial results for the year ended 31 December 2024, including key highlights, financial tables (revenue, operating profit, EPS), management commentary, and future outlook. It is structured as a press release (RNS) and provides the core financial data for the period, fitting the definition of an Earnings Release perfectly. FY 2024
2025-02-26 English
Notice of Results
Report Publication Announcement Classification · 99% confidence The document is a short announcement (4246 characters) released via RNS (London Stock Exchange news service). The core content states that Hikma Pharmaceuticals PLC "will announce its financial results for the year ended 31 December 2024 on Wednesday 26 February 2025." It also provides details for the subsequent Q&A call. Because the document is an announcement about the future publication of results, rather than the results themselves (like an ER or 10-K), and it is being distributed through a regulatory news service, it fits the definition of a Report Publication Announcement (RPA). It is not a general regulatory filing (RNS) because it is specifically announcing the publication of a financial report.
2025-02-10 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is identified by the RNS Number (1175R) and explicitly mentions 'Notification and public disclosure of transactions by A Person Discharging Managerial Responsibilities ("PDMR")' concerning the 'Disposal of Shares'. This directly corresponds to the definition of Director's Dealing (insider trades) as per the provided categories. The structure, referencing MAR Article 19, confirms this is a regulatory filing detailing insider transactions. Therefore, the appropriate code is DIRS.
2024-12-23 English
Outcome of Audit Tender Process
AGM Information Classification · 99% confidence The document is a short announcement released via RNS (London Stock Exchange news service), indicated by the 'RNS Number' and the footer information. The content explicitly discusses the 'Outcome of Audit Tender Process,' specifically announcing the reappointment of PwC as the external auditor and noting that further details will be in the 2024 Annual Report & Accounts. Since this is an announcement about an audit-related decision and not the full Audit Report itself (Code: AR), and it is a formal regulatory disclosure, it fits best under the general Regulatory Filings category (RNS), as it is not a specific announcement like a dividend (DIV) or management change (MANG). Given the short length and the nature of reporting a specific corporate event via the RNS system, RNS is the most appropriate classification.
2024-11-07 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.